Age : pleural fluid ADA ratio and other indicators for differentiating between tubercular and malignant pleural effusions

Jiupeng Zhou, MM, Yuanli Yang, MM, Yongfeng Zhang, MM, Heng Liu, MM, Quanli Dou MM*

Abstract
Most of pleural effusions are caused by tuberculosis and malignant tumor. Difficult sampling and bacterial sparing nature of these diseases challenge doctors’ diagnosis in China.

This study aimed to develop a new convenient and effective method for the differentiation of tuberculous and malignant pleural effusion.

A prospective cohort study of patients hospitalized with malignant (n = 90) and tuberculosis (n = 130) pleural effusions from September 2018 to October 2020 was performed. The diagnostic performance of the age to pleural fluid ADA ratio (age/ADA) and other indicators to distinguish tuberculous and malignant pleural effusions was evaluated by receiver operating characteristic (ROC) curve analysis.

The areas under the curve (AUC) of age/ADA and pleural fluid ADA were largest. Age/ADA showed sensitivity and specificity of 81.5% (95%CI 73.8%–87.8%) and 97.8% (95%CI 92.2%–99.7%) respectively. The sensitivity and specificity of pleural fluid ADA were 83.1% (95%CI 75.5%–89.1%) and 93.3% (95%CI 86.1%–97.5%) respectively. The positive likelihood (36.69 (95%CI 9.3–144.8)) of age/ADA was significantly higher than that of pleural fluid ADA [12.46 (95%CI 5.7–27.1)]. The AUCs for Cancer Ratio and Cancer Ratio plus were lower and showed a sensitivity of 80.0% (95%CI 72.1%–86.5%), 80.0% (95%CI 70.2%–87.7%) and a specificity of 81.5% (95%CI 73.8%–87.8%), 80.0% (95%CI 70.2%–87.7%) respectively.

Age/ADA has a higher diagnostic accuracy than ADA. Age/ADA is a promising diagnostic index for tuberculous and malignant pleural effusion with high sensitivity and specificity, especially the high positive likelihood ratio. The diagnostic accuracy of Cancer Ratio and Cancer Ratio plus are inferior to those of age/ADA and ADA.

Abbreviations: ADA = adenosine deaminase, age/ADA = the ratio of age and pleural effusion ADA, AUC = areas under the curve, Cancer Ratio = serum LDH = pleura fluid ADA ratio, Cancer Ratio plus = the ratio of Cancer Ratio to pleural fluid lymphocyte count, LDH = lactate dehydrogenase, MPE = malignant pleural effusion, NLR = negative likelihood ratio, PE = Pleural effusion, PLR = positive likelihood ratio, ROC = receiver operating characteristic, TPE = Tuberculous pleural effusion.

Keywords: age/ADA ratio; Cancer Ratio; Cancer Ratio plus; pleural effusion

1. Introduction
Pleural effusion (PE) is common in the emergency department, respiratory department, or chest diseases.[1] Tuberculous pleural effusion (TPE), malignant pleural effusion (MPE), and parapneumonic pleural effusion are the most common cause of clinical exudative pleural effusion.[2] Difficult sampling and bacterial sparing nature of these diseases challenge doctors’ diagnosis. Especially, TPE and MPE are the most difficult to be distinguished.

For the past few years, some more advanced tests have been designed to identify the origin of PE. A meta-analysis including 20 studies indicated that the overall estimates of the sensitivity/specificity for differentiating MPE were as below: CEA+CA125, 0.65/0.98, CEA+CA15-3, 0.64/0.98, CEA+CA19-9, 0.58/0.98, CEA+CYFRA21-1, 0.82/0.92, and CA15-3+CYFRA21-1, 0.88/0.94.[1] Al thought the detection of tumor markers has certain potential, their sensitivity and specificity are not satisfactory. Moreover, they are often costly and lack of operability. The summary sensitivity and specificity of Xpert MTB/RIF were 30% (95%CI: 21%–42%) and 99% (95%CI: 97%–100%) for diagnosing tuberculous pleurisy in Zhen-Yu Huo’s meta-analysis.[4] This method of combining a pleural lactate dehydrogenase (LDH) to adenosine deaminase (ADA) ratio and a pleural CEA level had a sensitivity of 62.0% and a specificity of 91.0%.[5] Similarly, sensitivity was not satisfactory.

The initial treatment decision, based on the changes of biochemical markers, such as LDH, ADA level and lymphocyte percentage in PE, is critical. So, Piotr claimed lately that age to

This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
pleural fluid ADA ratio (age/ADA) was characterized by high sensitivity (93.2%) and fair specificity (71.2%) for differentiating MPE from non–MPE.[6] Verma reported serum LDH: pleural fluid ADA ratio (Cancer Ratio) showed sensitivity and specificity of 0.98 (95% CI 0.92–0.99) and 0.94 (95% CI 0.83–0.98) at a cut-off level of >20.[7] His other study showed that the sensitivity and specificity of Cancer Ratio: pleural fluid lymphocyte count (Cancer Ratio Plus), a cut-off level of >30 were 97.6% (95% CI 0.90–0.99) and 94.1% (95% CI 0.78–0.98).[8] These biochemical indicators are encouraging, but majority of these studies are retrospective and small sample. In addition, others' reports about these indicators are rare.

Consider the above factors, our purpose is forward-looking to assess the effectiveness of age/ADA in differentiating TPE and MPE, and evaluate the ability of “Cancer Ratio” and “Cancer Ratio Plus” in differentiating TPE and MPE.

2. Methods

2.1. Data collection

This study is a study of diagnostic accuracy. We prospectively enrolled patients with PE hospitalized from September 2018 to October 2020. Patients who participated in the study either showed signs of PE when they first went to Xi’an Chest Hospital, or had PE during hospitalization undergoing chest CT scan visited to Xi’an Chest Hospital, or had pleural effusion during hospitalization undergoing chest CT scan. Patients who had transudative effusion and parapneumonic pleural effusion (PPE) were removed. All patients involved in this study gave their written informed consent. Minors (<18 years old) were not included in the study. The study obtained approval from the Ethics Committee of Xi’an Chest Hospital. MPE was diagnosed by malignant pleural fluid cytology or malignant pleural biopsy histology. TPE was defined by growth of mycobacterium tuberculosis on pleural fluid, including polymerase chain reaction or epithelioid granuloma in pleural biopsy tissue. The pathological results were judged by 2 professional pathologists. Tuberculosis on pleural fluid was confirmed by malignant pleural fluid cytology or malignant pleural biopsy histology. The pathologists and laboratory physicians were blind to the results of the other test and to any other clinical information.

To estimate the group size, we calculated the sample size according to the sensitivity and specificity of age/ADA reported by Piotr. With α = 0.05, 2-tailed and a power of 90%, we needed 25 patients in TPE group and 79 patients in MPE group. Considering a compliance rate of 90%, we asked 28 TPE patients and 88 MPE patients to participate in this study.

These parameters from patients who participated in the study either showed signs of PE when they first went to Xi’an Chest Hospital, or had pleural effusion during hospitalization undergoing chest CT scan were assessed, including patient gender, age, final diagnosis, fever, abnormal lump (lump > 1 cm revealed physical or imaging examination), C-reactive protein, serum lactate dehydrogenase (LDH), and pleural fluid biochemical parameters (LDH, ADA, pleural fluid lymphocyte count).

2.2. Three ratios were defined

1. The ratio of age and PE ADA (age/ADA): this ratio to assess the accuracy of combining age with PE ADA to identify TPE and MPE.

2. Cancer Ratio was described as serum LDH: pleural fluid ADA ratio, which was a predictive factor of tuberculous pleural effusion.

3. The ratio of Cancer Ratio to pleural fluid lymphocyte count was called as Cancer Ratio plus. This is calculated to be prospective to evaluate the effectiveness of differentiating TPE and MPE.

2.3. Statistical analysis

Statistical analysis was carried out by MedCalc 18.0 (MedCalc Software, Ostende, Belgium) software package. The data were described by median and quartile in skewed distribution and mean and standard deviation in normal distribution. The normality of a distribution for the continuous variables was assessed by Kolmogorov-Smirnov test. The Kruskal-Wallis test was used for the difference of continuous variables. Differences of categorical variables were analyzed by Chi square test. A multivariate logistic regression analysis was used to analyze the variables with difference by kruskal-Wallis test or chi square test. The diagnostic performance of the variables associated with TPE shown by multivariate logistic regression analysis to distinguish TPE and MPE were evaluated by receiver operating characteristic (ROC) curve, consisting of area under the curve (AUC) and 95% confidence interval (CIs). ROC curves were compared by Delong test, which represented the diagnostic performance of different tests. P < 0.05 was considered statistical significance.

3. Results

A total of 261 patients were recruited who either showed signs of PE when they first visited to Xi’an Chest Hospital, or had PE during hospitalization. Three patients younger than 18 years old were excluded. Twenty-three patients were removed who had transudative effusion (n = 16) and PPE (n = 7). A total of 235 patients was tested in the study. In index test negative group (age/ADA > 2.65, n = 118), 5 patients were not diagnosed because 2 patients died before diagnosis and 3 patients refused to undergo pathological or etiological tests. One patient was not confirmed by pathology or etiology. In index test positive group (age/ADA ≤ 2.65, n = 117), 7 patients were not diagnosed because 3 patients died before diagnosis and 4 patients refused to undergo pathological or etiological tests. Two patients were not confirmed by pathology or etiology. Finally, a total of 220 patients was included in the study.

There were 90 patients with MPEs (40.9%), 130 patients with TPEs (59.1%). The primary causes of MPE included: primary lung cancer (n = 68), pleural metastatic carcinoma of unknown origin (n = 8), mesothelioma (n = 6), gastric carcinoma (n = 4), carcinoma of urinary bladder (n = 2), and lymphoma (n = 2). General clinical features and selected biochemical parameters of patients with MPE and TPE were shown in Table 1. There were only conventional symptomatic treatment including oxygen inhalation, nutritional support, etc, without any special treatment, such as antituberculosis, antiinfection or antiinflammatory treatment between the index tests and reference standard. There were 1 case of hemothorax and 2 cases of pneumothorax from performing the index test or the reference standard.

Univariate analysis showed that there was not remarkable difference in gender, more than 5 years smoking history, pleural fluid LDH, serum LDH and pleural fluid lymphocyte count between the 2 groups. Pleural fluid ADA and C-reactive protein increased in tuberculous pleural effusion. In addition, the age of malignant PE group was significantly older and the fever rate was significantly lower. When combined with age, serum LDH, pleural fluid ADA and pleural fluid lymphocyte count, there were greater differences between the 2 groups (Table 1).

We further evaluated the independent influences on TPE of the parameters with difference shown by univariate analysis. In multivariate logistic regression analysis, Fever (OR = 58.695, P = 0.013) and pleural fluid ADA (OR = 1.276, P < 0.001) were positive predictive factors of tuberculous pleural effusion. In contrast, Age/pleural fluid ADA (OR = 0.456, P < 0.001), Cancer Ratio (OR = 0.880, P = 0.025), Cancer Ratio plus (OR = 0.902, P = 0.025) and abnormal lump (OR = 0.020, P = 0.001) maintained significance as negative predictive factors of tuberculous pleural effusion. C-reactive protein (OR = 1.089, P =
Table 1
General clinical features and selected biochemical parameters in patients.

| Variable                  | Total (N = 220) | MPE (N = 90) | TPE (N = 130) | P value |
|---------------------------|-----------------|--------------|---------------|---------|
| Age                       | 56(32–69)       | 64(56–75)    | 39(24.75–62.75) | <0.001  |
| Gender (male/female)      | 142/78          | 52/38        | 90/40         | 0.081   |
| More than 5 years smoking | 102/118         | 36/54        | 66/64         | 0.115   |
| Fever (yes/no)            | 70/150          | 10/80        | 60/70         | <0.001  |
| Abnormal lump             | 81/139          | 66/24        | 15/115        | <0.001  |
| Pleural fluid ADA         | 22.5(9–42)      | 98–12.25     | 38(25.5–51)   | <0.001  |
| Pleural fluid LDH         | 687.83 ± 458.91 | 672.42 ± 334.37 | 724.66 ± 553.11 | 0.076   |
| Serum LDH                 | 516.15 ± 415.71 | 555.38 ± 436.39 | 459.48 ± 379.10 | 0.003   |
| C-reactive protein        | 29.34(9.54–55.96) | 20.56(33–93.35) | 41.25(13.61–80.68) | 0.001   |
| Age/ADA                   | 2.83(0.83–7.22) | 6.89(4.80–11.21) | 1.06(0.58–1.97) | <0.001  |
| Cancer ratio              | 19.16(10.96–38.33) | 40.62(30.08–62.66) | 12.51(8.95–17.52) | <0.001  |
| Cancer ratio plus         | 0.80(0.78–0.80) | 0.80(0.76–0.80) | 0.80(0.78–0.80) | 0.229   |
| Pleural fluid lymphocyte count | 26.28(13.35–54.11) | 54.22(15–81.33) | 13.99(11.29–22.21) | <0.001  |

Table 2
Multivariate logistic regression analysis with TPE as the outcome variable.

| Variable                  | Coefficient | Standard error | Exp (B) | lower         | Upper         | P value |
|---------------------------|-------------|----------------|---------|---------------|---------------|---------|
| Age                       | -0.002      | 0.025          | 0.998   | 0.951         | 1.047         | 0.921   |
| Fever                     | 4.072       | 1.636          | 58.695  | 2.375         | 1450.591      | 0.013   |
| Pleural fluid ADA         | 0.243       | 0.057          | 1.276   | 1.142         | 4.125         | 0.000   |
| C-reactive protein        | 0.041       | 0.017          | 1.089   | 0.928         | 0.993         | 0.433   |
| Age/ADA                   | -0.784      | 0.209          | 0.456   | 0.303         | 0.688         | 0.000   |
| Cancer ratio              | -0.127      | 0.057          | 0.880   | 0.787         | 0.984         | 0.025   |
| Cancer ratio plus         | -0.105      | 0.046          | 0.902   | 0.825         | 0.927         | 0.020   |
| Abnormal lump             | -3.891      | 1.208          | 0.0481  | 4.590         | 522.682       | 0.001   |
sensitivity and specificity in Piotr’s study based on MPE. The sensitivity and specificity of pleural fluid ADA were 83.1% (95% CI 75.5–89.1%) and 93.3% (95% CI 86.1–97.5%) respectively at cut-off level of >21.5. A meta-analysis also showed that the sensitivity and specificity of ADA in the diagnosis of tuberculosis pleural effusion were 0.93 and 0.90, respectively.[15] ADA is an enzyme in lymphocytes and myeloid cells. It is indispensable for DNA metabolism and citoactive. It can recycle the poisonous purine way of metabolites. ADA levels are usually ascended in inflammatory effusions, such as pleural, pericardial and articular effusions caused by bacterial infection and granulomatous inflammation, as well as malignant tumors and autoimmune diseases.[16,17] Though the AUC of pleural fluid, ADA was slightly larger compared with age/ADA (Z = 0.346, P = 0.7297, Fig. 1A, B), the PLR of age/
ADA was 36.69 and was considerably higher than that of pleural fluid ADA. This meant that patients were 36.69 times more likely to have tuberculous pleural effusion than not when age/ADA ≤ 2.65. This probability was high enough to suggest that the pleural effusion would be likely to be tuberculous. This suggested that age/ADA was more advantageous in differentiating tuberculous and malignant pleural effusion than ADA alone. There was no significant difference in the negative predictive value between age/ADA and pleural fluid ADA.

We found that the sensitivity and specificity of Cancer Ratio were 80.0% (95%CI 72.1%–86.5%) and 80.0% (95%CI 70.2%–87.7%) respectively at cut-off level of ≤21.24 and the AUC was 0.859 (Fig. 1C), which were significantly lower than the pooled sensitivity (0.97) and specificity (0.89) of Cancer Ratio shown in the meta-analysis of Yan Qiu Han.[18] The results were also significantly different from what were reported by Verma[7] and Piotr.[6] The sensitivity and specificity of Cancer Ratio plus were found to be 81.5% (95%CI 73.8%–87.8%) and 80.0% (95%CI 70.2%–87.7%) respectively at the cut-off level of ≤34.74 in our study (Fig. 1D). This difference might be related to different inclusion standard and the different features of the research objects. One reason was that the benign PE group was different. The proportions of patients with TPE and PPE were 26% and 21% in Piotr’s study.[6] TPE constituted only 28.8% in the study by Verma.[7] His other study included 40 patients with tubercular effusion, 14 with parapneumonic effusion, and 9 with undiagnosed PE, 24.5%, 8.5%, and 5.5%.[7] Similarly, this result was obviously inferior to that in Verma’s previous research. This difference might be related to different inclusion standard and the different features of the research objects. One reason was that the benign PE group was different. The proportions of patients with TPE and PPE were 26% and 21% in Piotr’s study.[6] TPE constituted only 28.8% in the study by Verma.[7] His other study included 40 patients with tubercular effusion, 14 with parapneumonic effusion, and 9 with undiagnosed PE, 24.5%, 8.5%, and 5.5%.[7] In our study, patients with tuberculous PE accounted for 59.1%. The other reason was that the proportion of lung cancer in malignant PE group was different. Lung cancer accounted for 95% and 97.6% of malignant PE respectively in both studies of Verma.[7] In Piotr’s study, malignant PE contained 51.4% of lung cancer patients.[6] The proportions of patients with lung cancer were 75.6% in our study. Serum lactate dehydrogenase (LDH) is an extensive cellular enzyme that increases in a non-specific manner in response to tissue damage. It was found that serum LDH was increased in many clinical cases.[19] We also found that serum LDH was higher in patients with malignant PE, which was consistent with previous reports.[7,20] The level of serum LDH may be related to the type and metastasis of tumor, and the inclusion of more advanced cancer cases and different types of patients may lead to different sensitivity and specificity.

In addition, though fever was a positive predictor of tuberculous PE, while abnormal lung was negative, the sensitivity and specificity of the both methods were poor in differentiating tuberculous and malignant PE.

The present study had 2 limitations. First, we did not study exudative effusion caused by other diseases, such as parapneumonic effusion, to verify the outcomes in this group of patients. Second, lung cancer accounted for a large proportion in patients with malignant PE.

All in all, our study shows that age/ADA has a higher diagnostic accuracy than ADA. Age/ADA is a promising diagnostic index for tuberculous and malignant PE with high sensitivity and specificity, especially the high positive likelihood ratio. The diagnostic accuracy of Cancer Ratio and Cancer Ratio plus are inferior to those of age/ADA and ADA. However, as a result of the limitations of our study, further studies need to be carried out to demonstrate our results.

**Author contributions**

Conceptualization: Jiupeng Zhou, Quanli Dou; Data curation: Jiupeng Zhou; Funding acquisition: Jiupeng Zhou, Quanli Dou; Investigation: Yuani Yang, Yongfeng Zhang; Methodology: Jiupeng Zhou, Heng Liu; Project administration: Quanli Dou; Software: Jiupeng Zhou; Roles/Writing – original draft: Jiupeng Zhou; Writing – review & editing: Quanli Dou.

**References**

[1] Porcel JM, Azzopardi M, Koegelenberg CF, et al. The diagnosis of pleural effusions. Expert Rev Respir Med. 2015;9:801–13.
[2] Light RW. Clinical practice. Pleural effusion. N Engl J Med. 2002;346:1971–7.
[3] Yang Y, Liu YL, Shi HZ. Diagnostic accuracy of combinations of tumor markers for malignant pleural effusion: an updated meta-analysis. Respiration. 2017;94:62–9.
[4] Hsu YP, Peng L. Is Xpert Mtb/RIF appropriate for diagnosing tuberculous pleurisy with pleural fluid samples? A systematic review. BMC Infect Dis. 2018;18:284.
[5] Saraya T, Ohkuma K, Koide T, et al. A novel diagnostic method for distinguishing parapneumonic effusion and empyema from other diseases by using the pleural lactate dehydrogenase to adenosine deaminase ratio and carcinoembryonic antigen levels. Medicine (Baltimore). 2019;98:e15003.
[6] Korczynski P, Mierzejewski M, Krenke R, et al. Cancer ratio and other new parameters for differentiation between malignant and nonmalignant pleural effusions. Pol Arch Intern Med. 2018;128:334–41.
[7] Verma A, Abhisheganaden J, Light RW. Identifying malignant pleural effusion by a cancer ratio (Serum LDH: Pleural Fluid ADA Ratio). Lung. 2016;194:147–53.
[8] Verma A, Dagaonkar RS, Marshall D, et al. Differentiating malignant from tuberculous pleural effusion by cancer ratio plus (cancer ratio: pleural lymphocyte count). Can Respir J. 2016;2016:7348239.
[9] Kang JY, Rhee CK, Kang NH, et al. Clinical utility of two interferon-γ release assays on pleural fluid for the diagnosis of tuberculous pleurisy. Tuberc Respir Dis (Seoul). 2012;73:143–50.
[10] Ruan SY, Chuang YC, Wang JY, et al. Revisiting tuberculous pleurisy: pleural fluid characteristics and diagnostic yield of mycobacterial culture in an endemic area. Thorax. 2012;67:822–7.
[11] Polish National Cancer Registry. Overall number of malignancies. Available at: http://onkologia.org.pl/notoryzatory-ziolisiowe-ogolem-2/. [access date October 2020].
[12] Cancer Research UK-Lung Cancer. Available at: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer#headingZero. [access date January 2018].
[13] Zhang X, Andersen AB, Lillevang T, et al. Effect of sex, age, and race on the clinical presentation of tuberculosis: a 15-year population-based study. Am J Trop Med Hyg. 2011;85:285–90.
[14] Aggarwal AN, Agarwal R, Sekhal IS, et al. Adenosine deaminase for diagnosis of tuberculous pleural effusion: A systematic review and meta-analysis. PLoS One. 2019;14:e0213728.
[15] Arroyo M, Soberman JE. Adenosine deaminase in the diagnosis of tuberculous pericardial effusion. Am J Med Sci. 2008;335:227–9.
[16] Reuter H, Burgess L, van Vuuren W, et al. Diagnosing tuberculous pleurisy with pleural fluid samples? A systematic review. BMC Infect Dis. 2018;18:284.
[17] Han YQ, Zhang L, Yan L, et al. Diagnostic accuracy of cancer ratio for malignant pleural effusion: a systematic review and meta-analysis. Ann Transl Med. 2019;7:554.
[18] Sugita O. [Lactate dehydrogenase]. Rinsho Byori. 1984;32:357–62.
[19] Goldman RD, Kaplan NO, Hall TC. Lactic dehydrogenase in human neoplastic tissues. Cancer Res. 1964;24:389–99.